email@email.com
Request a Call
Contact Online
Subscribe |
| Log In
The most widely read newsletter on China's life science industry.
Toggle navigation
Home
Subscribe
Top Stories
Hot Topics
Search
Conferences
Consulting
About Us
Contact Us
You are here:
All Products
Articles
Instant access to selected
ChinaBio® Today
subscriber-only articles.
Browse
All Products
Articles
Viewing
2101 - 2115
of 3630 products
View All
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
Next
EOC Pharma Raises $71 Million in C Round for China Development of In-Licensed Oncology Drugs
$5.00
Available
Munich's ViGeneron Closes Series A from WuXi and Sequoia for Gene Therapies
$5.00
Available
Pharmaron Stages $434 Million Hong Kong IPO, after Completing Shenzhen IPO in January
$5.00
Available
Clover Biopharma Completes $43 Million Financing for Biologic Drug Development
$5.00
Available
Ennovabio Closes $14 Million Series A Round for Novel Drug Development
$5.00
Available
GensKey Raises $14 Million for Genetics-based Diagnosis of Pathogens
$5.00
Available
Merck Announces Third Approval of Keytruda for Lung Cancer in China
$5.00
Available
Innovent and Hanmi Start China Trials of PD-1/HER2 Bispecific
$5.00
Available
Chi-Med's Surufatinib Granted Orphan Status in US
$5.00
Available
Lee's Pharm Affiliate Conducting China Phase III Trial of Combo Treatment for Severe Acne
$5.00
Available
Ascentage Building Headquarters, R&D Center, Manufacturing Facility in Suzhou
$5.00
Available
CStone Starts Bridging Trial of Leukemia Treatment in China
$5.00
Available
Clover Starts Fifth Clinical Trial of TRAIL-Trimer Fusion Candidate
$5.00
Available
BrightGene Completes $74 Million Shanghai Star Board IPO; Trades 141% Higher
$5.00
Available
Lansion Bio Closes $14 Million C Round for IVD Portfolio
$5.00
Available